**Methods** 64 CHF patients were randomised equally into two groups. All were treated with the basic conventional treatment. Additionally, 1.2 g of QC was given three times a day to the therapy group, while no additional treatment was given to the control group. During the treatment, body weight, urine output, sweat secretion and 6 min walking distance were observed in the two groups. The dosage of cedilanid and furosemide for the first week and second week in the two groups was analysed. The levels of serum Na⁺ in two groups were respectively measured on the second, eighth and fifteenth hospital day. During the treatment, the side-effect and compliance were observed.

**Results** 1 and 2 weeks after treatment, the number of sweat secretion was less in two groups, but the decrement was more significantly in the therapy group than in the control group (p<0.05). One week later, the urine output was more than that before (p<0.05), body weight became less (p<0.05), and 6 min walking distance was better than before, but there are all no significant differences between two groups (p>0.05). 2 weeks later, in both groups, the urine output was more than that before; body weight became less; 6 min walking distance was better than before. All these differences are significant differences statistically (p<0.05). And there are significant differences about urine output and 6 min walking distance between two groups statistically (p<0.05); about body weight between two groups there is no significant difference (p>0.05). There are no significant differences about the dosage of lanatoside C and furosemide in the first and second week between two groups statistically (p>0.05). The level of serum Na⁺ on the eighth hospital day was less than before in both groups (p<0.05), but there are no significant differences between two groups statistically (p>0.05); on the fifteenth day, there is almost no change about that of the therapy group compared with that on the eighth day (p>0.05); on the contrary, there is a significant difference in the control group statistically (p<0.05); and there is a significant difference between two groups statistically (p<0.05). During the period of using the capsule, the 35 patients have not any uncomfortable complain about this drug and nobody stop using this capsule.

**Conclusion** The effect of QC about releasing hyperidrosis in a short time is conspicuous. It can play the role in a short time. There is no obvious effect on body weight. The short-term effects of QC about improving urine output and 6 min walking distance are not significant, but it plays this role during the second week gradually. QC can’t reduce the dosage of cedilanid and furosemide. QC has the effect of keeping the level of serum Na⁺ to some extent. During the observation, the tolerance of this capsule is good, and there is no side effect observed.

---

**Methods** 42 children (male 19, female 23, age 7 days~14 years) diagnosed of atrial tachycardia were treated by oral anti-arrhythmic drugs. 24 h holter monitoring and wireless remote realtime monitoring system were used to evaluate the efficacy. Cardiac function was evaluated by echocardiogram. Side effects of drugs were closely detected during the whole process.

**Results** 21 cases were firstly treated by single sotalol, none were completely cured, 20 were partially cured (95.2%), 1 was ineffective (4.8%). 41 cases were finally treated by sotalol plus propafenone, 30 were completely cured (73.2%), 9 were partially cured (21.9%) and 2 were ineffective (4.9%). The effective dose of sotalol was 5.4~5.7 mg/kg.d, and the effective dose of propafenone was 9~10.5 mg/kg.d. 5 cases of incessant atrial tachycardia complicated by tachycardiomyopathy (5/17, 29.4%) were treated by amiodarone plus metprolol, 1 was completely cured and the others’ cardiac function were obviously improved after treatment although none of them were completely cured, they all reverted to sotalol plus propafenone while cardiac function became nearly normal. Injury of thyroid function happened in 3 cases after taking oral amiodarone for 5~8 months and all recovered during 1 month after withdrawing the drug. During the 1~14 months of follow up for the 31 cases completely cured, only 1 case of intermittent atrial tachycardia recurred at No.8 month after withdrawing the drug.

**Conclusion** 1. Sotalol is a safe and effective anti-arrhythmic drug which can be used to treat paediatric atrial tachycardia, effective dose is 4.89~5.71 mg/kg.d; 2. Combination use of sotalol plus propafenone is obviously more effective than single use of sotalol with satisfactory safety; 3. Combination use of sotalol plus propafenone is safer and more effective than combination use of amiodarone plus metprolol. 4. Amiodarone might lead to thyroid function injury, and can be used as transitional drug for patients diagnosed of tachycardiomyopathy.
**Conclusions** QT/RR slope of DCM sudden death group was higher than DCM non sudden death and Con group significantly. QT/RR slope show high predicting value for sudden death in DCM patients independently or combined with NSVT or LVEF.

**Method**

We measured the ABI of 775 cases of hospitalised cardiovascular-event high-risk patients. ABI<0.9 and ABI>1.3 are defined as abnormal. Collected data and process statistics analysis to investigate the independent risk factors of ABI.

**Results**

The incidence of abnormal ABI is 54%. Among them ABI<0.9 have 12.4%, Independent risk factors to predict ABI abnormalities are: sex, age, diabetes, creatinine abnormalities, mellitus, hypertension, high cholesterol, high smoking. In cardiovascular-event high-risk ABI<0.9 and ABI>1.3 all show obvious difference. The ABI no show obvious difference in difference clan.

**Conclusions** In patients with cardiovascular-event high-risk ABI<0.9 and ABI>1.3 are abnormal. ABI abnormalities are particularly prevalent in the old, smokers and patients with hypertension, diabetes or dyslipidemia. The difference of ABI between each clan did not show statistics to learn the difference.

**Conclusion** Taurine can prevent the formation of atherosclerosis and inhibit the apoptosis of VSMCs in the atherosclerotic plaque by regulating the bcl-2, bax and caspase-3 proteins.